SeaStar Medical Announces FDA Approval of Reduction in Mandatory Enrollment for SAVE Surveillance Registry Evaluating QUELIMMUNE™ Safety for Pediatric AKI

Rhea-AI Summary

SeaStar Medical (Nasdaq: ICU) announced the FDA's Center for Biologics Evaluation and Research approved reducing the mandatory SAVE Surveillance Registry enrollment from 300 to 50 patients for post‑approval monitoring of QUELIMMUNE, the pediatric AKI therapy approved in 2024.

To date, 32 pediatric patients have been entered, and early registry data from the first 21 patients showed zero device‑related adverse events and improved survival (76% at Day 28/60; 71% at Day 90). SeaStar estimates the U.S. pediatric AKI market at $100 million and says the reduction should ease adoption and commercial rollout.

Positive

• Mandatory registry reduced from 300 to 50 patients
• 32 patients entered into SAVE to date
• Zero device‑related adverse events reported in first 21 patients
• Survival outcomes: 76% at Day 28/60 and 71% at Day 90
• Potential to expand addressable U.S. pediatric AKI market of $100M

Negative

• Registry enrollment and setup slowed adoption at medical centers
• Current dataset remains small (32 patients entered) for definitive conclusions

News Market Reaction – ICU

+8.28%

5 alerts

+8.28% News Effect

+19.8% Peak in 27 min

+$937K Valuation Impact

$12M Market Cap

0.1x Rel. Volume

On the day this news was published, ICU gained 8.28%, reflecting a notable positive market reaction. Argus tracked a peak move of +19.8% during that session. Our momentum scanner triggered 5 alerts that day, indicating moderate trading interest and price volatility. This price movement added approximately $937K to the company's valuation, bringing the market cap to $12M at that time.

Data tracked by StockTitan Argus on the day of publication.

Key Figures

SAVE registry requirement: 50 patients Original registry requirement: 300 patients Patients entered: 32 pediatric patients +5 more

8 metrics

SAVE registry requirement 50 patients Revised FDA-mandated SAVE Surveillance Registry size

Original registry requirement 300 patients Initially required SAVE Surveillance Registry enrollment under HDE

Patients entered 32 pediatric patients Total entered into SAVE Surveillance Registry to date

Survival at Day 28/60 76% survival First 21 pediatric patients with AKI and sepsis on QUELIMMUNE

Survival at Day 90 71% survival First 21 pediatric patients with AKI and sepsis on QUELIMMUNE

Historical survival 50% survival rate Typical survival for comparable pediatric AKI patients cited by company

Registry efficacy subset 21 patients First SAVE Surveillance Registry cohort with detailed outcomes

Pediatric AKI market $100 million Estimated total U.S. pediatric AKI market opportunity

Market Reality Check

Price: $2.64 Vol: Volume 454,621 is well be...

low vol

$2.64 Last Close

Volume Volume 454,621 is well below 20-day average of 3,387,038 (relative volume 0.13) ahead of this news. low

Technical Shares at $0.341 are trading below the 200-day MA of $0.96 and far under the $3.07 52-week high.

Peers on Argus

Peer moves are mixed, with names like AKTX up 4.33% and NRXS, ENLV down over 4%,...

1 Down

Peer moves are mixed, with names like AKTX up 4.33% and NRXS, ENLV down over 4%, suggesting today’s FDA-related catalyst is stock-specific for ICU.

Historical Context

5 past events · Latest: Dec 02 (Positive)

Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Dec 02	FDA post-approval change	Positive	+8.3%	FDA cut SAVE registry from 300 to 50 patients on QUELIMMUNE safety data.
Nov 20	Investor conference	Neutral	-0.4%	Announcement of CEO presentation at NobleCon21 investor conference.
Nov 17	CFO appointment	Positive	-20.3%	New CFO with extensive healthcare finance and IPO experience appointed.
Nov 13	Earnings and pipeline	Negative	-7.8%	Q3 loss, modest revenue, going-concern needs and larger NEUTRALIZE-AKI enrollment.
Nov 05	Earnings date set	Neutral	-2.6%	Scheduling of Q3 2025 results call and recap of QUELIMMUNE approval status.

Pattern Detected

ICU has shown mixed reactions: operational/financial updates (earnings, conferences) often saw modest declines, while today’s FDA-related news saw a positive move, and one major management hire drew a sharp selloff.

Recent Company History

Over the last month, SeaStar reported Q3 2025 results with early QUELIMMUNE revenue, ongoing losses, and a need for additional capital, followed by a new CFO appointment on Nov 17 and an investor conference appearance. Regulatory filings outlined an at-the-market program and a proposed 1-for-10 reverse split to address Nasdaq bid-price compliance. Against this backdrop, today’s FDA decision to cut the SAVE registry requirement to 50 patients advances the QUELIMMUNE post-approval strategy.

Market Pulse Summary

The stock moved +8.3% in the session following this news. A strong positive reaction aligns with the...

Analysis

The stock moved +8.3% in the session following this news. A strong positive reaction aligns with the FDA decision to cut the SAVE registry size to 50 patients and early survival rates of 76% at 28/60 days and 71% at 90 days. Historically, some FDA-related news produced weaker or even negative moves, so a large gain could reflect renewed focus on QUELIMMUNE’s commercial potential. However, recent filings show reliance on equity financing and plans for a reverse split, factors that could weigh on longer-term sustainability.

Key Terms

humanitarian device exemption, post-approval study, renal replacement therapy, selective cytopheretic device, +1 more

5 terms

humanitarian device exemption regulatory

"as outlined in the original Humanitarian Device Exemption (HDE) approval"

A humanitarian device exemption is a regulatory pathway that lets a medical device be approved for use in treating or diagnosing very small patient groups without the usual proof that it works as well as larger treatments; think of it as a special permit for products that serve rare conditions. It matters to investors because it can speed market access and reduce development cost, but the patient pool and sales potential are small and reimbursement or wider adoption may be uncertain.

post-approval study regulatory

"The SAVE Surveillance Registry is a Post-Approval Study (PAS) that is designed"

A post-approval study is a research program regulators require or companies choose to run after a drug or medical device is already approved and sold, to track real-world safety, longer-term effectiveness, or performance in broader patient groups. Investors care because results can change product labels, sales forecasts, or trigger additional costs and restrictions—think of it as a warranty-era check that can alter a product’s market value and legal risk.

renal replacement therapy medical

"pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT)"

Renal replacement therapy is medical treatment that takes over the job of failing kidneys by removing waste and excess fluid from the blood, most commonly through dialysis or by restoring kidney function with a transplant. Investors care because these therapies drive demand for machines, supplies, drugs and ongoing care services, creating predictable revenue streams, regulatory and reimbursement risks, and sensitive cost pressures—think of it as a lifeline device market that must be paid for continuously.

selective cytopheretic device medical

"QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy"

A selective cytopheretic device is a medical blood‑filter used outside the body to temporarily capture and calm overactive immune cells that drive dangerous inflammation in critically ill patients. Think of it as a traffic cop that pulls aside aggressive drivers so the rest of the system can flow—this can lower organ damage, shorten intensive‑care stays and reduce costs. Investors watch it for clinical trial results, regulatory approval and hospital adoption, which determine market potential and reimbursement.

hyperinflammation medical

"broad applications for treating the destructive hyperinflammation that shuts down organ function"

An excessive, uncontrolled immune response that causes collateral damage to the body’s own tissues, like a fire brigade spraying so much water that it floods a building while putting out a blaze. Investors should care because hyperinflammation can drive severe illness, change clinical trial outcomes, increase treatment costs, create demand for new drugs or diagnostics, and influence regulatory decisions and market potential for therapies targeting inflammatory conditions.

AI-generated analysis. Not financial advice.

FDA lowers surveillance requirement to 50 patients from 300 patients in original HDE approval based on assessment of first 21 SAVE Surveillance Registry patients 

Compelling efficacy data to date along with completion of registry expected to expand QUELIMMUNE market opportunity

DENVER, Dec. 02, 2025 (GLOBE NEWSWIRE) -- SeaStar Medical Holding Corporation (Nasdaq: ICU), a commercial-stage healthcare company, announced today the Center for Biologics Evaluation and Research (CBER) of the U.S. Food and Drug Administration (FDA) has approved a reduction in the mandatory enrollment size of the SAVE Surveillance Registry from the originally-required 300 patients to only 50 patients. This new 50-patient registry size will satisfy the post-approval surveillance requirement by the FDA as outlined in the original Humanitarian Device Exemption (HDE) approval and indicates that FDA believes that continued device safety can be successfully shown with fewer patients than originally required.

The SAVE Surveillance Registry is a Post-Approval Study (PAS) that is designed to confirm the safety of the QUELIMMUNE therapy, which was approved in 2024 as a treatment for children with acute kidney injury (AKI) and sepsis or a septic condition. To date, data from 32 pediatric patients have been entered into the SAVE Surveillance Registry.

“We are grateful for this decision by the FDA and believe, once the registry is complete, it will enable us to expand the potential organ-sparing and life-saving benefits of our QUELIMMUNE therapy to more pediatric patients with AKI,” stated Eric Schlorff, CEO of SeaStar Medical. “These kids typically have about a 50% survival rate and our data from the first 21 patients in the SAVE Surveillance Registry showed zero device-related adverse events and a clear improvement to 70% survival at 90 days. This decision is a win-win for patients, their families, health care providers, and the overall health care system. We thank the FDA for their rapid evaluation of the required enrollment size of the mandatory surveillance requirements for the registry.”

Preliminary results from the SAVE Surveillance Registry were recently presented at the 5th International Symposium on Acute Kidney Injury in Children. The SAVE Surveillance Registry presentation highlighted the role of QUELIMMUNE (Selective Cytopheretic Device for Pediatrics, or SCD-PED) therapy in the treatment of critically ill pediatric patients with life-threatening Acute Kidney Injury (AKI) and sepsis requiring Renal Replacement Therapy (RRT). Data from the first 21 pediatric patients with AKI and sepsis requiring RRT showed zero device-related adverse events or infections and no reports of immunosuppressive effects by the device. In addition, outcomes analyses show a 76% survival rate at Day 28 and Day 60, and a 71% survival rate at Day 90. These new data are on track to validate a 50% reduction in loss of life compared to historical data, as reported in Kidney Medicine.

“The SAVE Surveillance Registry has provided valuable clinical outcomes data on both the safety and efficacy of our QUELIMMUNE therapy, but it has also slowed the adoption process and potential to treat these pediatric patients due to the complexities of setting up and running a patient registry at these medical institutions,” stated Tim Varacek, Senior Vice President, Commercial and Business Operations. “There has been very strong interest in QUELIMMUNE adoption and we are pleased that we can satisfy FDA’s registry requirements with far fewer patients than expected, enabling a smoother adoption process and potentially expanding the revenue opportunity to capture a larger portion of the total pediatric AKI market which we estimate to be about $100 million in the U.S. alone.”

The QUELIMMUNE therapy has been adopted by some of the highest rated children’s medical centers in the United States. The patented technology behind QUELIMMUNE is known as the Selective Cytopheretic Device (SCD) therapy and has broad applications for treating the destructive hyperinflammation that shuts down organ function and causes loss of life.

About Acute Kidney Injury (AKI) and Hyperinflammation 

AKI is characterized by a sudden and temporary loss of kidney function and can be caused by a variety of conditions such as sepsis, severe trauma, surgery, and COVID-19. AKI can cause destructive hyperinflammation, which is the overproduction or overactivity of inflammatory effector cells and other molecules that can be toxic. Damage resulting from this destructive hyperinflammation in AKI can progress to other organs, such as the heart or liver, and potentially to multi-organ dysfunction or even failure that could result in worse outcomes, including increased risk of death. Even after resolution, these patients may face complications including chronic kidney disease or end-stage renal disease (ESRD) requiring dialysis. Extreme hyperinflammation may also contribute to added healthcare costs, such as prolonged ICU stays and increased reliance on dialysis and mechanical ventilation.

About QUELIMMUNE

The QUELIMMUNE™ therapy is being commercialized for children with AKI and sepsis or septic condition weighing 10 kilograms or more who are on antibiotics and being treated in the ICU with Renal Replacement Therapy (RRT). It was approved in February 2024 under a HDE application that requires medical institutions to also participate in the SAVE Surveillance Registry and complete Institutional Review Board approvals prior to adoption and use of the QUELIMMUNE therapy. This prolongs the adoption timeline by medical institutions, but provides important data on the use of QUELIMMUNE in the “real-world” setting.

Data from two clinical studies of the QUELIMMUNE therapy, published in Kidney Medicine, showed a 77% survival rate in patient treated with QUELIMMUNE versus standard of care, representing an approximate 50% reduction in loss of life compared to historical data in this patient population. No dialysis was required for survivors and 87.5% of survivors had normal kidney function at Day 60 after ICU discharge. Recent data presented from the first 21 patients in the SAVE Surveillance Registry mirror the clinical trial results.

In January 2025, SeaStar Medical was awarded the 2025 Corporate Innovator Award by the National Kidney Foundation for its significant contribution to improving the lives of pediatric patients with AKI based on the approval and introduction of the QUELIMMUNE therapy.

About the NEUTRALIZE-AKI Pivotal Trial 

The NEUTRALIZE-AKI (NEUTRophil and monocyte deActivation via SeLective Cytopheretic Device – a randomIZEd clinical trial in Acute Kidney Injury) pivotal trial is evaluating the safety and efficacy of the SCD therapy in 200 adults with AKI in the ICU receiving CRRT. The trial’s primary endpoint is a composite of 90-day mortality or dialysis dependency of patients treated with the SCD therapy in addition to CRRT as the standard of care, compared with the control group receiving only CRRT standard of care. Secondary endpoints include mortality at 28 days, ICU-free days in the first 28 days, major adverse kidney events at Day 90 and dialysis dependency at one year. The study will also include subgroup analyses to explore the effectiveness of the SCD therapy in AKI patients with sepsis and acute respiratory distress syndrome. 

About the SeaStar Medical Selective Cytopheretic Device Therapy

The Selective Cytopheretic Device (SCD) therapy is designed as a disease-modifying device that neutralizes over-active immune cells and stops the cytokine storm that yields destructive hyperinflammation and creates a cascade of events that wreak havoc in the patient’s body. The SCD therapy has broad applications in multiple acute and chronic kidney and cardiovascular diseases, representing patients who today have no FDA-approved options for treating their disease. Unlike pathogen removal and other blood-purification tools, the SCD therapy is integrated with an existing CRRT hemofiltration system to selectively target and transition proinflammatory monocytes to a reparative state and promote activated neutrophils to be less inflammatory. This unique immunomodulation approach may promote long-term organ recovery, eliminate the need for future RRT, including dialysis, and prevent loss of life.

About SeaStar Medical

SeaStar Medical is a commercial-stage healthcare company focused on transforming treatments for critically ill patients facing organ failure and potential loss of life. SeaStar’s first commercial product, QUELIMMUNE (SCD-PED), was approved in 2024 by the U.S. Food and Drug Administration (FDA). It is the only FDA approved product for the ultra-rare condition of life-threatening acute kidney injury (AKI) due to sepsis or a septic condition in critically ill pediatric patients. SeaStar’s Selective Cytopheretic Device (SCD) therapy has been awarded Breakthrough Device Designation for six therapeutic indications by the FDA, enabling the potential for a speedier pathway to approval and preferable reimbursement dynamics at commercial launch. The company is currently conducting a pivotal trial of its SCD therapy in adult patients with AKI requiring continuous renal replacement therapy (CRRT), a life-threatening condition with no effective treatment options that impacts over 200,000 adults in the U.S. annually.

For more information visit www.seastarmedical.com or visit us on LinkedIn or X.

Forward-Looking Statements 

This press release contains certain forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1955. These forward-looking statements include, without limitation, SeaStar Medical’s expectations with respect to the anticipated adoption our products; anticipated cost savings for patients, healthcare providers, and the healthcare system more generally from the adoption of the SCD therapy; the total addressable market for pediatric SCD applications; the ability of SeaStar Medical to increase market share and generate sales with respect to the total addressable market for pediatric SCD applications; the ability of SCD to treat patients with AKI and other diseases; the expected regulatory approval process and timeline for commercialization; and the ability of SeaStar Medical to meet the expected timeline. Words such as “believe,” “project,” “expect,” “anticipate,” “estimate,” “intend,” “strategy,” “future,” “opportunity,” “plan,” “may,” “should,” “will,” “would,” “will be,” “will continue,” “will likely result,” and similar expressions are intended to identify such forward-looking statements. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to significant risks and uncertainties that could cause the actual results to differ materially from the expected results. Most of these factors are outside SeaStar Medical’s control and are difficult to predict. Factors that may cause actual future events to differ materially from the expected results include, but are not limited to: (i) the risk that SeaStar Medical may not be able to obtain regulatory approval of its SCD product candidates; (ii) the risk that SeaStar Medical may not be able to raise sufficient capital to fund its operations, including current or future clinical trials; (iii) the risk that SeaStar Medical and its current and future collaborators are unable to successfully develop and commercialize its products or services, or experience significant delays in doing so, including failure to achieve approval of its products by applicable federal and state regulators, (iv) the risk that SeaStar Medical may never achieve or sustain profitability; (v) the risk that SeaStar Medical may not be able to secure additional financing on acceptable terms; (vi) the risk that third-party suppliers and manufacturers are not able to fully and timely meet their obligations, (vii) the risk of product liability or regulatory lawsuits or proceedings relating to SeaStar Medical’s products and services, (viii) the risk that SeaStar Medical is unable to secure or protect its intellectual property, and (ix) other risks and uncertainties indicated from time to time in SeaStar Medical’s Annual Report on Form 10-K, including those under the “Risk Factors” section therein and in SeaStar Medical’s other filings with the SEC. The foregoing list of factors is not exhaustive. Forward-looking statements speak only as of the date they are made. Readers are cautioned not to put undue reliance on forward-looking statements, and SeaStar Medical assumes no obligation and do not intend to update or revise these forward-looking statements, whether as a result of new information, future events, or otherwise. 

Contact:  
IR@SEASTARMED.COM

FAQ

What did the FDA approve regarding the SAVE Surveillance Registry for QUELIMMUNE (ICU) on December 2, 2025?

The FDA approved reducing the mandatory SAVE registry enrollment requirement from 300 to 50 patients.

How many pediatric patients have been entered into the SAVE Surveillance Registry for QUELIMMUNE (ICU)?

32 pediatric patients have been entered into the registry to date.

What safety and efficacy results did SeaStar report from the first 21 SAVE registry patients for QUELIMMUNE (ICU)?

Data from the first 21 patients showed zero device‑related adverse events and survival of 76% at Day 28/60 and 71% at Day 90.

How might the FDA's reduction to a 50‑patient registry affect QUELIMMUNE adoption and commercialization (ICU)?

SeaStar says the smaller registry should ease adoption by simplifying setup and could accelerate commercial rollout and revenue expansion.

What is SeaStar's estimate of the U.S. pediatric AKI market for QUELIMMUNE (ICU)?

SeaStar estimates the U.S. pediatric AKI market at about $100 million.